Natco Pharma Limited has announced its third interim dividend for the financial year 2025-26, demonstrating the company's commitment to returning value to shareholders. The pharmaceutical company's Board of Directors approved the dividend declaration during their meeting held on February 12, 2026.

Dividend Declaration Details

The company has declared an interim dividend with specific parameters that shareholders should note:

This marks the third interim dividend payment by the company for the current financial year, indicating consistent cash flow generation and management's confidence in the business performance.

Eligibility and Payment Timeline

Shareholders who are on the company's records as of the close of business on February 18, 2026, will be eligible to receive the interim dividend payment. The company has established a clear timeline for the dividend process, with payments scheduled to begin on February 26, 2026.

The dividend amount of Rs 1.50 represents 75% of the face value of each equity share, which is valued at Rs 2.00. This calculation demonstrates the substantial return being provided to shareholders through this interim distribution.

Regulatory Compliance

The dividend declaration has been made in accordance with Regulation 42 of the Securities and Exchange Board of India (SEBI) regulations. The company has duly informed both major stock exchanges where its shares are listed - BSE Limited (Scrip Code: 524816) and National Stock Exchange of India Limited (Scrip Code: NATCOPHARM).

The announcement was signed by Ch. Venkat Ramesh, Company Secretary and Compliance Officer, ensuring proper corporate governance procedures were followed in the dividend declaration process.

Natco Pharma has received regulatory approval from the High Court to manufacture semaglutide and export the diabetes medication to select nations. This significant judicial decision opens new manufacturing opportunities for the pharmaceutical company in the diabetes treatment market.

Regulatory Approval Details

The High Court's permission allows Natco Pharma to commence production of semaglutide, a medication primarily used for treating type 2 diabetes and weight management. The approval specifically covers manufacturing rights along with export permissions to certain countries, though the specific nations were not detailed in the court order.

Market Implications

This regulatory clearance positions Natco Pharma to enter the semaglutide market segment, which has seen growing demand globally. The medication belongs to a class of drugs known as GLP-1 receptor agonists, widely prescribed for diabetes management and weight control.

The court's decision represents a notable development for the company's pharmaceutical manufacturing portfolio, potentially expanding its presence in the diabetes care segment. The export approval component of the ruling suggests opportunities for international market expansion in select jurisdictions.